Trials / Unknown
UnknownNCT02975115
Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization
The Catholic University of Korea Cancer Research Institute
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 102 (actual)
- Sponsor
- Seoul St. Mary's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to confirm the efficacy of dasatinib 100mg once daily in producing a complete molecular response and to prove a possibility of "Operational Cure" in CMR patients.
Detailed description
This study also examines kinetics of complete molecular responses using new highly sensitive PCR based technology, digital PCR, which is reported to have a sensitivity down to 6 log reduction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | RQ-PCR RNA Analysis | Conventional Q-RT-PCR every 3 months |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2016-11-01
- Completion
- 2018-01-01
- First posted
- 2016-11-29
- Last updated
- 2016-11-29
Source: ClinicalTrials.gov record NCT02975115. Inclusion in this directory is not an endorsement.